Read the First Edition of The Lens, a new magazine by LSI arrow-icon
Published January 2020 | Forecasts through 2024
Global Opportunities in Neurostimulation Technologies Markets Targeting Chronic Pain
Reports Graph
Overview

The global market for neurostimulation devices targeting chronic pain was estimated at $2.52 billion in 2018, comprised almost exclusively of spinal cord stimulation (SCS) systems. Peripheral nerve stimulation (PNS) represent a much newer development that has only emerged as a meaningful segment with the introduction of next-generation products featuring miniature neurostimulators that communicate with external power sources via wireless technology.  Global sales of these next generation PNS systems were estimated at only $13.3 million in 2018 but are expected to see 34.7% real annual sales growth through 2024 to nearly $80 million as device sales increase from 2,000 in 2018 to 11,675 in 2024.  A detailed analysis of the global neurostimulation devices market and the competitive landscape is included in this new report.

Buy Global Opportunities in Neurostimulation Technologies Markets Targeting Chronic Pain
Companies Covered

Abbott/St. Jude Medical

Bioness

BlueWind

Boston Scientific

Medtronic

Mainstay

Nalu Medical

Nevro

Nuvectra

Saluda Medical

SPR Therapeutics

Stimwave

Other Emerging Players

Order individually or subscribe and
get a complete intel platform.

Trusted By The Companies Pioneering What’s Next